CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?

Shares of gene therapy specialist, CRISPR Therapeutics (NASDAQ: CRSP) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first treatment from the Food and Drug Administration (FDA), but the stock price is way down.Investment bank analysts up and down Wall Street have noticed the disconnect between CRISPR Therapeutics' recent accomplishments and its stock price. The average analyst following the drug developer stock thinks it can soar to $78.20 per share in the year ahead.The consensus target implies a gain of about 106% from the stock's price that fell below $38 per share on May 19. While the potential rewards are high, so are the risks. Here's a closer look to see if this stock could be a good fit for your portfolio.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool